2 protocol(s) meet the specified criteria
Drug: BAY 43-9006
Protocol No.TitleStatus
AAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
BTCRC-GI13-002An Open Label Randomized Phase I/II Trial of TAK-228 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular CarcinomaOpen